Ebola virus disease (EVD), also known as Ebola haemorrhagic fever in humans and other primates, is a serious, frequently fatal sickness. Ebola Virus Disease (EVD) is a devastating disease that affects both humans and nonhuman primates. After becoming infected with the virus, symptoms often appear two to three weeks later. Fever, sore throat, muscle soreness, and headaches are generally the first signs. Vomiting, diarrhoea, dermatitis, and reduced liver and renal function are common side effects, and some people bleed internally and externally as a result. The disease kills between 25% and 90% of people affected, with an average death rate of 50%. The most common cause of death is shock from fluid loss, which happens six to 16 days after the first symptoms show. Direct contact with infected body fluids, such as blood from infected humans or other animals, or contact with items that have recently been contaminated with infected body fluids, is how the virus spreads.
Zika virus disease is caused by a virus that is mostly transmitted by Aedes mosquitoes that bite during the day. Fever, rash, conjunctivitis, muscle and joint discomfort, malaise, and headache are all common symptoms. The symptoms usually persist 2–7 days. The majority of those infected with the Zika virus do not experience any symptoms. In Africa, the Americas, Asia, and the Pacific, Zika virus outbreaks have been reported.
Title : The role of the humoral innate immune system in evasion of streptococcus pyogenes infections
Francis J. Castellino, University of Notre Dame, United States
Title : Global climate change and mosquito-borne diseases in coastal areas
Ranjan Ramasamy, IDFISH Technology, United States
Title : The impact of global antibiotic resistance on the healthcare system, public health, environment and society
Reza Nassiri, Michigan State University, United States
Title : Current topics of adult COVID-19, Influenza, and RS virus patients in Japan
Seki Masafumi, Saitama Medical University International Medical Center, Japan
Title : Impressive virologic suppression of SHIV infection with long-term AAV delivery of monoclonal antibodies
Ronald Desrosiers, University of Miami Miller School of Medicine, United States
Title : Novel nanotechnology and its potential applications
Stephen Hsu, Augusta University, United States